Smithfield Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Smithfield Trust’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15	Closed	-$3K	–	1006
2023 Q3	$3K	Hold	15	–	–	﹤0.01%	949
2023 Q2	$3K	Hold	15	–	–	﹤0.01%	966
2023 Q1	$3K	Hold	15	–	–	﹤0.01%	935
2022 Q4	$3K	Hold	15	–	–	﹤0.01%	930
2022 Q3	$3K	Hold	15	–	–	﹤0.01%	965
2022 Q2	$2K	Hold	15	–	–	﹤0.01%	1031
2022 Q1	$3K	Hold	15	–	–	﹤0.01%	1025
2021 Q4	$3K	Hold	15	–	–	﹤0.01%	1026
2021 Q3	$3K	Hold	15	–	–	﹤0.01%	1052
2021 Q2	$3K	Hold	15	–	–	﹤0.01%	1023
2021 Q1	$2K	Hold	15	–	–	﹤0.01%	1066
2020 Q4	$2K	Hold	15	–	–	﹤0.01%	1053
2020 Q3	$2K	Hold	15	–	–	﹤0.01%	1032
2020 Q2	$2K	Buy	+15	New	+$2.02K	﹤0.01%	953

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Smithfield Trust's ALNY Position: Q4 2023 in Review

Smithfield Trust sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 15 shares — an estimated $3K sold.

Smithfield Trust first reported a position in ALNY in Q2 2020 and held it in 14 quarters. The position peaked at $3K in Q3 2023. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

Smithfield Trust reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Smithfield Trust sold 15 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $3K.
Smithfield Trust first reported a position in Alnylam Pharmaceuticals in Q2 2020 and held it in 14 quarters.
Smithfield Trust's Alnylam Pharmaceuticals position peaked at $3K in Q3 2023.
499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Smithfield Trust's 13F filing for Q4 2023, filed 7 Feb 2024.